A second chance for a PPARγ targeted therapy?
Department of Pharmacology Roy J and Lucille A Carver College of Medicine University of Iowa, Iowa City, Iowa 52242, USA.
Andrew W
AW
Norris
Curt D
CD
Sigmund
D054392:Adipokines / Q000378:metabolism; D001713:Biphenyl Compounds / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007333:Insulin Resistance; D008024:Ligands; D047495:PPAR gamma / Q000187:drug effects*; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
C561901:(S)-4'-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; D054392:Adipokines; D001713:Biphenyl Compounds; D007004:Hypoglycemic Agents; D008024:Ligands; D047495:PPAR gamma; D045162:Thiazolidinediones